Aditya Acquisition Company

Sun Pharmaceutical Industries (Sun Pharma) is a leading global specialty generic pharmaceutical company based in Mumbai, India. It is the largest pharmaceutical company in India and holds a significant presence in the United States and other international markets. The company focuses on a broad range of therapeutic areas, including dermatology, ophthalmology, neurology, and psychiatry. In 2023, Sun Pharma completed the acquisition of Concert Pharmaceuticals through its subsidiary, Aditya Acquisition Subsidiary Limited, to bolster its specialty dermatology portfolio. This acquisition brought in deuruxolitinib (Leqselvi), an oral JAK inhibitor for the treatment of alopecia areata, which received FDA approval in 2024. Sun Pharma's business model combines a strong foundation in high-quality generics with a growing pipeline of innovative specialty products. The company operates over 40 manufacturing facilities and serves patients in more than 100 countries worldwide.